African sleeping sickness

BMJ. 2008 Mar 29;336(7646):679-80. doi: 10.1136/bmj.39505.490544.BE. Epub 2008 Mar 5.

Abstract

Eflornithine should be the drug of choice for stage 2 disease, but resistance must be monitored

Publication types

  • Comment
  • Editorial

MeSH terms

  • Drug Resistance
  • Eflornithine / therapeutic use*
  • Humans
  • Trypanocidal Agents / therapeutic use*
  • Trypanosomiasis, African / drug therapy*

Substances

  • Trypanocidal Agents
  • Eflornithine